FDA Issues Draft Guides for Generic Drug Approvals
Published Date: 12/5/2025
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by February 3, 2026, before these guides become final. These updates aim to speed up drug approvals and keep costs down for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Draft guidances for generic drug studies
If you make generic drugs, the FDA posted new draft and revised draft product-specific guidances that give recommendations on how to design bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists specific active ingredients covered (see Tables 1 and 2) and these guidances are available on FDA's website.
FDA says updates aim to speed approvals
The notice states these updates aim to speed up drug approvals and keep costs down for everyone. If that occurs, consumers could see faster availability of generic drugs and lower drug costs.
Opportunity to comment by Feb 3, 2026
You may submit electronic or written comments on these draft guidances; to ensure the FDA considers your input before it begins work on the final version, submit comments by February 3, 2026. Instructions for electronic and paper submissions and how to submit confidential material are provided in the notice.
Guidances are non-binding; alternatives allowed
The draft guidances represent the FDA's current thinking but do not establish rights and are not binding. You may use an alternative approach if it satisfies applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
Previous / Next Documents
Previous: 2025-22129, Sunshine Act Meeting Notice
The Federal Trade Commission is holding a secret meeting on December 9, 2025, to discuss a law enforcement issue. This meeting is closed to the public, so no one outside the Commission will hear the details. It affects anyone interested in FTC actions but doesn’t signal any immediate money changes or public deadlines.
Next: 2025-22132, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is holding a virtual meeting on January 13-14, 2026, to review research progress and discuss grant applications. Scientists, researchers, and grant applicants will be affected as some sessions are open to the public while others are private to protect personal info. This meeting helps decide funding and research directions but doesn’t announce new money or deadlines yet.